In contrast to most approved therapies for prostate cancer, the life-prolonging, bone-homing radiopharmaceutical 223radium dichloride (Ra-223) and the therapeutic vaccine sipuleucel-T exert their therapeutic benefits with only modest declines in serum prostate-specific antigen (PSA) concentrations [13–15]. This evidence concerns the gene KLK3 and Familial prostate cancer.